Sophie M T Wehrens, Mikko Arvas, Suzanne F Fustolo-Gunnink, Matea Vinković Vlah, Allison Waters, Christian Erikstrup, Louise Ørnskov Drechsler, Simon J Stanworth, Katja van den Hurk
{"title":"Opportunities for vein-to-vein datasets from a blood establishment perspective: Towards a 'Pan-European Transfusion Research InfrAstructure'.","authors":"Sophie M T Wehrens, Mikko Arvas, Suzanne F Fustolo-Gunnink, Matea Vinković Vlah, Allison Waters, Christian Erikstrup, Louise Ørnskov Drechsler, Simon J Stanworth, Katja van den Hurk","doi":"10.1111/vox.70340","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>The 'Pan-European Transfusion Research InfrAstructure' (PETRA) project was established to advance the use of donor, blood product and patient datasets in Europe, aiming to benefit both patient and donor health. Here, the initial PETRA objective was to describe the landscape of existing donor and blood establishment (BE) databases.</p><p><strong>Materials and methods: </strong>An online survey was circulated to the European Blood Alliance's BE-members. The survey collected information on the feasibility of accessing donor data, and challenges and possibilities for linking these datasets with information on the associated blood products and transfusion recipients, and donors' own health records.</p><p><strong>Results: </strong>Seventeen BEs across 16 countries completed the survey. The majority could, in principle, link their donor data to product data (13 BEs, 76%) and recipient data (10 BEs, 59%) for research purposes. However, capabilities were limited and in only 5 of 17 BEs was the donor to recipients' linkage an automated process. BEs reported significant challenges to achieve full vein-to-vein linkage, including legal constraints and lack of consent (11 BEs) and resources (10-14 BEs). Information technology and data issues as well as lack of knowledge and training were cited as obstacles by a minority of BEs.</p><p><strong>Conclusion: </strong>Whilst the survey results suggest considerable interest in developing linkages between blood donors, their products and recipients, many challenges remain due to a variety of obstacles. First steps in working towards a PETRA may be assistance to navigate legal frameworks as well as investing in resources and quality and harmonization of data collections.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70340","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: The 'Pan-European Transfusion Research InfrAstructure' (PETRA) project was established to advance the use of donor, blood product and patient datasets in Europe, aiming to benefit both patient and donor health. Here, the initial PETRA objective was to describe the landscape of existing donor and blood establishment (BE) databases.
Materials and methods: An online survey was circulated to the European Blood Alliance's BE-members. The survey collected information on the feasibility of accessing donor data, and challenges and possibilities for linking these datasets with information on the associated blood products and transfusion recipients, and donors' own health records.
Results: Seventeen BEs across 16 countries completed the survey. The majority could, in principle, link their donor data to product data (13 BEs, 76%) and recipient data (10 BEs, 59%) for research purposes. However, capabilities were limited and in only 5 of 17 BEs was the donor to recipients' linkage an automated process. BEs reported significant challenges to achieve full vein-to-vein linkage, including legal constraints and lack of consent (11 BEs) and resources (10-14 BEs). Information technology and data issues as well as lack of knowledge and training were cited as obstacles by a minority of BEs.
Conclusion: Whilst the survey results suggest considerable interest in developing linkages between blood donors, their products and recipients, many challenges remain due to a variety of obstacles. First steps in working towards a PETRA may be assistance to navigate legal frameworks as well as investing in resources and quality and harmonization of data collections.
期刊介绍:
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.